0001558370-23-010552.txt : 20230526 0001558370-23-010552.hdr.sgml : 20230526 20230526163633 ACCESSION NUMBER: 0001558370-23-010552 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20230524 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230526 DATE AS OF CHANGE: 20230526 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ampio Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001411906 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 260179592 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35182 FILM NUMBER: 23969648 BUSINESS ADDRESS: STREET 1: 373 INVERNESS PARKWAY STREET 2: SUITE 200 CITY: ENGLEWOOD STATE: CO ZIP: 80112 BUSINESS PHONE: 720-437-6500 MAIL ADDRESS: STREET 1: 373 INVERNESS PARKWAY STREET 2: SUITE 200 CITY: ENGLEWOOD STATE: CO ZIP: 80112 FORMER COMPANY: FORMER CONFORMED NAME: Chay Enterprises, Inc. DATE OF NAME CHANGE: 20070910 8-K 1 ampe-20230524x8k.htm 8-K
0001411906false--12-3100014119062023-05-242023-05-24

​

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) 

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 24, 2023

AMPIO PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

​

​

​

​

Delaware

001-35182

26-0179592

(State or other jurisdiction of
incorporation)

(Commission File Number)

(IRS Employer Identification No.)

​

373 Inverness Parkway, Suite 200

Englewood, Colorado 80112

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (720) 437-6500

​

Not Applicable

(Former name, or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.0001 par value

AMPE

NYSE American

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

Item 3.03.

Material Modification to Rights of Security Holders.

​

The disclosure set forth in Item 5.03 below is hereby incorporated herein by reference.

 

Item 5.03.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

​

Bylaw Amendment

​

On May 24, 2023, the board of directors the (“Board”) of Ampio Pharmaceuticals, Inc. (the “Company”), adopted and approved an amendment to the Company’s Amended and Restated Bylaws (the “Bylaws Amendment”) in order to change the proportion of shares present required to constitute a quorum at a meeting of stockholders, from a majority to one-third of the outstanding shares of stock entitled to vote.

​

The foregoing description of the Bylaws Amendment does not purport to be complete and is qualified in its entirety by the text of the Bylaws Amendment, which is filed as Exhibit 3.1 to this Current Report and is incorporated herein by reference.

​

Series D Preferred Stock

​

On May 24, 2023, the Board declared a dividend of one one-thousandth of a share of Series D Preferred Stock, par value $0.0001 per share (“Series D Preferred Stock”), for each outstanding share of common stock of the Company, par value $0.0001 per shares (the “Common Stock”) to stockholders of record at 5:00 p.m. Eastern Time on June 8, 2023 (the “Record Date”).

​

General; Transferability. Shares of Series D Preferred Stock will be uncertificated and represented in book-entry form. No shares of Series D Preferred Stock may be transferred by the holder thereof except in connection with a transfer by such holder of any shares of Common Stock held by such holder, in which case a number of one one-thousandth (1/1,000th) of a share of Series D Preferred Stock equal to the number of shares of Common Stock to be transferred by such holder will be automatically transferred to the transferee of such shares of Common Stock.

​

Voting Rights. Each share of Series D Preferred Stock will entitle the holder thereof to 1,000,000 votes per share (and, for the avoidance of doubt, each fraction of a share of Preferred Stock will have a ratable number of votes). Thus, each one-thousandth of a share of Series D Preferred Stock would entitle the holder thereof to 1,000 votes. The outstanding shares of Series D Preferred Stock will vote together with the outstanding shares of Common Stock of the Company as a single class exclusively with respect to (i) any proposal to adopt an amendment to the Company’s Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to effect a reverse stock split of the outstanding shares of Common Stock at a ratio determined in accordance with the terms of such amendment (the “Reverse Stock Split”), and (ii) any proposal to adjourn any meeting of stockholders called for the purpose of voting on Reverse Stock Split (the “Adjournment Proposal”). The Series D Preferred Stock will not be entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law.

​

Unless otherwise provided on any applicable proxy or ballot with respect to the voting on the Reverse Stock Split or the Adjournment Proposal, the vote of each share of Series D Preferred Stock (or fraction thereof) entitled to vote on the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split and the Adjournment Proposal will be cast in the same manner as the vote, if any, of the share of Common Stock in respect of which such share of Series D Preferred Stock (or fraction thereof) was issued as a dividend is cast on the Reverse Stock Split, the Adjournment Proposal, or such other matter, as applicable, and the proxy or ballot with respect to shares of Common Stock held by any holder on whose behalf such proxy or ballot is submitted will be deemed to include all shares of Series D Preferred Stock (or fraction thereof) held by such holder. Holders of Series D Preferred Stock will not receive a separate ballot or proxy to cast votes with respect to the Series D Preferred Stock on the Reverse Stock Split, the Adjournment Proposal, or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split.

​

Dividend Rights. The holders of Series D Preferred Stock, as such, will not be entitled to receive dividends of any kind.

​

Liquidation Preference. The Series D Preferred Stock will rank senior to the Common Stock, as to any distribution of assets upon a liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily (a “Dissolution”). Upon any Dissolution, each holder of outstanding shares of Series D Preferred Stock will be entitled to be paid out of the assets of the Company available for distribution to stockholders, prior and in preference to any distribution to the holders of Common Stock, an amount in cash equal to $0.001 per outstanding share of Series D Preferred Stock.

​

Redemption. All shares of Series D Preferred Stock that are not present in person or by proxy at any meeting of stockholders held to vote on the Reverse Stock Split and the Adjournment Proposal as of immediately prior to the opening of the polls at such meeting (the “Initial Redemption Time”) will automatically be redeemed in whole, but not in part, by the Company at the Initial Redemption Time without further action on the part of the Company or the holder of shares of Series D Preferred Stock (the “Initial Redemption”). Any outstanding shares of Series D Preferred Stock that have not been redeemed pursuant to an Initial Redemption will be redeemed in whole, but not in part, (i) if such redemption is ordered by the Board in its sole discretion, automatically and effective on such time and date specified by the Board in its sole discretion or (ii) automatically upon the approval by the Corporation’s stockholders of the Reverse Stock Split at any meeting of the stockholders held for the purpose of voting on such proposal.

​

Each share of Series D Preferred Stock redeemed in any redemption described above will be redeemed in consideration for the right to receive an amount equal to $0.01 in cash for each ten whole shares of Series D Preferred Stock that are “beneficially owned” by the “beneficial owner” (as such terms are defined in the certificate of designation with respect to the Series D Preferred Stock (the “Certificate of Designation”)) thereof as of immediately prior to the applicable redemption time and redeemed pursuant to such redemption, payable upon receipt by the Company of a written request submitted by the applicable holder to the corporate secretary of the Company (each a “Redemption Payment Request”) following the applicable Redemption Time. Such Redemption Payment Request shall (i) be in a form reasonably acceptable to the Company, (ii) set forth in reasonable detail the number of shares of Series D Preferred Stock beneficially owned by the holder at the applicable redemption time and include evidence reasonably satisfactory to the Company regarding the same, and (iii) set forth a calculation specifying the amount in cash owed to such holder by the Company with respect to the shares of Series D Preferred Stock that were redeemed at the applicable redemption time. However, the redemption consideration in respect of the shares of Series D Preferred Stock (or fractions thereof) redeemed in any redemption described above: (i) will entitle the former beneficial owners of less than ten whole shares of Preferred Stock redeemed in any redemption to no cash payment in respect thereof and (ii) will, in the case of a former beneficial owner of a number of shares of Series D Preferred Stock (or fractions thereof) redeemed pursuant to any redemption that is not equal to a whole number that is a multiple of ten, entitle such beneficial owner to the same cash payment, if any, in respect of such redemption as would have been payable in such redemption to such beneficial owner if the number of shares (or fractions thereof) beneficially owned by such beneficial owner and redeemed pursuant to such redemption were rounded down to the nearest whole number that is a multiple of ten (such, that for example, the former beneficial owner of 25 shares of Series D Preferred Stock redeemed pursuant to any redemption will be entitled to receive the same cash payment in respect of such redemption as would have been payable to the former beneficial owner of 20 shares of Series D Preferred Stock redeemed pursuant to such redemption).

Graphic

​

​

​

​

The Series D Preferred Stock is not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Series D Preferred Stock has no stated maturity and is not subject to any sinking fund. The Series D Preferred Stock is not subject to any restriction on the redemption or repurchase of shares by the Company while there is any arrearage in the payment of dividends or sinking fund installments.

​

The Certificate of Designation was filed with the Delaware Secretary of State and became effective on May 25, 2023. The foregoing description of the Series D Preferred Stock does not purport to be complete and is qualified in its entirety by reference to the Certificate of Designation, which is filed as Exhibit 3.2 to this Current Report and is incorporated herein by reference.

​

Item 7.01.

Regulation FD Disclosure.

​

On May 26, 2023, the Company issued a press release announcing the Series D Preferred Stock dividend. A copy of that press release is furnished as Exhibit 99.1 to this Current Report and incorporated herein by reference.

​

Item 9.01.

Financial Statements and Exhibits.

​

(d) Exhibits:

​

Exhibit No.

Description

3.1

Amendment to the Amended and Restated Bylaws of Ampio Pharmaceuticals, Inc. adopted May 24, 2023

3.2

Certificate of Designation of the Series D Preferred Stock of Ampio Pharmaceuticals, Inc. filed May 25, 2023

99.1

Ampio Pharmaceuticals, Inc. Press Release Announcing Series D Preferred Stock Dividend dated May 26, 2023

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

 

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

 

AMPIO PHARMACEUTICALS, INC.

 

 

 

 

 

Date:  May 26, 2023

By:

/s/ Michael A. Martino

 

 

 

Name: Michael A. Martino

 

 

 

Title: Chief Executive Officer

​

​

​

​

​

 EX-3.1 2 ampe-20230524xex3d1.htm EX-3.1

Exhibit 3.1

​

AMENDMENT TO THE

AMENDED AND RESTATED BYLAWS

OF AMPIO PHARMACEUTICALS, INC.

​

Effective May 24, 2023, Article III, Section 8 of the bylaws of Ampio Pharmaceuticals, Inc. was amended to read in its entirety as follows:

​

Section 8. Quorum. At all meetings of stockholders, except where otherwise provided by statute or by the Certificate of Incorporation, or by these Bylaws, the presence, in person, by remote communication, if applicable, or by proxy duly authorized, of the holders of one-third of the outstanding shares of stock entitled to vote shall constitute a quorum for the transaction of business. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time, either by the chairman of the meeting or by vote of the holders of a majority of the shares represented thereat, but no other business shall be transacted at such meeting. The stockholders present at a duly called or convened meeting, at which a quorum is present, may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Except as otherwise provided by statute, or by the Certificate of Incorporation or these Bylaws, in all matters other than the election of directors, the affirmative vote of a majority of shares present in person, by remote communication, if applicable, or represented by proxy duly authorized at the meeting and entitled to vote generally on the subject matter shall be the act of the stockholders. Except as otherwise provided by statute, the Certificate of Incorporation or these Bylaws, directors shall be elected by a plurality of the votes of the shares present in person, by remote communication, if applicable, or represented by proxy duly authorized at the meeting and entitled to vote generally on the election of directors. Where a separate vote by a class or classes or series is required, except where otherwise provided by the statute or by the Certificate of Incorporation or these Bylaws, one-third of the outstanding shares of such class or classes or series, present in person, by remote communication, if applicable, or represented by proxy duly authorized, shall constitute a quorum entitled to take action with respect to the vote on that matter. Except where otherwise provided by statute or by the Certificate of Incorporation or these Bylaws, the affirmative vote of the majority (plurality, in the case of the election of directors) of shares of such class or classes or series present in person, by remote communication, if applicable, or represented by proxy at the meeting shall be the act of such class or classes or series.

​

​

***

 EX-3.2 3 ampe-20230524xex3d2.htm EX-3.2

Exhibit 3.2

AMPIO PHARMACEUTICALS, INC.

CERTIFICATE OF DESIGNATION
OF
SERIES D PREFERRED STOCK

PURSUANT TO SECTION 151 OF THE
GENERAL CORPORATION LAW OF THE STATE OF DELAWARE

THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the board of directors of the Corporation (the “Board of Directors”), in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware, as amended (the “DGCL”), pursuant to a written consent executed on May 24, 2023, which resolution provides for the creation of a series of the Corporation’s Preferred Stock, par value $0.0001 per share, which is designated as “Series D Preferred Stock,” with the rights, powers and preferences, and the qualifications, limitations and restrictions thereof, set forth therein.

WHEREAS, the Certificate of Incorporation of the Corporation, as amended (the “Certificate of Incorporation”), provides for a class of capital stock of the Corporation known as preferred stock, consisting of 10,000,000 shares, par value $0.0001 per share (the “Preferred Stock”), issuable from time to time in one or more series, and further provides that the Board of Directors is expressly authorized, by resolution or resolutions, to provide, out of the unissued shares of Preferred Stock, for series of Preferred Stock and, with respect to each such series, to fix the number of shares constituting such series, and the designation of such series, the voting powers (if any) of the shares of such series, and the preferences and relative, participating, optional or other special rights, if any, and any qualifications, limitations or restrictions thereof, of the shares of such series, to the full extent now or hereafter permitted by the laws of the State of Delaware and the DGCL.

NOW, THEREFORE, BE IT RESOLVED, that, pursuant to authority conferred upon the Board of Directors by the Certificate of Incorporation, (i) a series of Preferred Stock be, and hereby is, authorized by the Board of Directors, (ii) the Board of Directors hereby authorizes the issuance of 50,000 shares of Series D Preferred Stock and (iii) the Board of Directors hereby fixes the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, of such shares of Preferred Stock, in addition to any provisions set forth in the Certificate of Incorporation that are applicable to all series of the Preferred Stock, as follows:

TERMS OF PREFERRED STOCK

1.Designation, Amount and Par Value. The series of Preferred Stock created hereby shall be designated as the Series D Preferred Stock (the “Series D Preferred Stock”), and the number of shares so designated shall be 50,000. Each share of Series D Preferred Stock shall have a par value of $0.0001 per share.

​

2.Dividends. The holders of Series D Preferred Stock, as such, shall not be entitled to receive dividends of any kind.

​

3.Voting Rights. Except as otherwise provided by the Certificate of Incorporation or required by law, the holders of shares of Series D Preferred Stock shall have the following voting rights:

​

3.1Except as otherwise provided herein, each outstanding share of Series D Preferred Stock shall have 1,000,000 votes per share (and, for the avoidance of doubt, each fraction of a share of Series D Preferred Stock shall have a ratable number of votes). The outstanding shares of Series D Preferred Stock shall vote together with the outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Corporation as a single class exclusively with respect to the Reverse Stock Split (as defined below) and the Adjournment Proposal (as defined below) and shall not be entitled to vote on any other matter except to the extent required under the DGCL. Notwithstanding the foregoing, and for the avoidance of doubt, each share of Series D Preferred Stock (or fraction thereof) redeemed pursuant to the Initial Redemption (as defined below) shall have no voting power with respect to, and the holder of each share of Series D Preferred Stock (or fraction thereof) redeemed pursuant to the Initial Redemption shall have no voting power with respect to any such share of Series D Preferred Stock (or fraction thereof) on, the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split. As used herein, the term “Reverse Stock Split” means any proposal to adopt an amendment to the Certificate of Incorporation to reclassify the outstanding shares of Common Stock into a smaller number of shares of Common Stock at a ratio specified in or determined in accordance with the terms of such amendment. As used herein, the term “Adjournment Proposal” means any proposal to adjourn any meeting of stockholders called for the purpose of voting on Reverse Stock Split.

​

3.2Unless otherwise provided on any applicable proxy or ballot with respect to the voting on the Reverse Stock Split or the Adjournment Proposal, the vote of each share of Series D Preferred Stock (or fraction thereof) entitled to vote on the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split and the Adjournment Proposal shall be cast in the same manner as the vote, if any, of the share of Common Stock (or fraction thereof) in respect of which such share of Series D Preferred Stock (or fraction thereof) was issued as a dividend is cast on the Reverse Stock Split, the Adjournment Proposal or such other matter, as applicable, and the proxy or ballot with respect to shares of Common Stock held by any holder on whose behalf such proxy or ballot is submitted will be deemed to include all shares of Series D Preferred Stock (or fraction thereof) held by such holder. Holders of Series D Preferred Stock will not receive a separate ballot or proxy to cast votes with respect to the Series D Preferred Stock on the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split.

​

4.Rank; Liquidation.

​

4.1The Series D Preferred Stock shall rank senior to the Common Stock as to any distribution of assets upon a liquidation, dissolution or winding up of the Corporation, whether voluntarily or involuntarily (a “Dissolution”). For the avoidance of any doubt, but without limiting the foregoing,

2

neither the merger or consolidation of the Corporation with or into any other entity, nor the sale, lease, exchange or other disposition of all or substantially all of the Corporation’s assets shall, in and of itself, be deemed to constitute a Dissolution.

​

4.2Upon any Dissolution, each holder of outstanding shares of Series D Preferred Stock shall be entitled to be paid out of the assets of the Corporation available for distribution to stockholders, prior and in preference to any distribution to the holders of Common Stock, an amount in cash equal to $0.001 per outstanding share of Series D Preferred Stock.

​

5.Redemption.

​

5.1All shares of Series D Preferred Stock that are not present in person or by proxy at any meeting of stockholders held to vote on the Reverse Stock Split and the Adjournment Proposal as of immediately prior to the opening of the polls at such meeting (the “Initial Redemption Time”) shall automatically be redeemed by the Corporation at the Initial Redemption Time without further action on the part of the Corporation or the holder thereof (the “Initial Redemption”).

​

5.2Any outstanding shares of Series D Preferred Stock that have not been redeemed pursuant to an Initial Redemption shall be redeemed in whole, but not in part, (i) if such redemption is ordered by the Board of Directors in its sole discretion, automatically and effective on such time and date specified by the Board of Directors in its sole discretion or (ii) automatically upon the approval by the Corporation’s stockholders of the Reverse Stock Split at any meeting of the stockholders held for the purpose of voting on such proposal (any such redemption pursuant to this Section 5.2, the “Subsequent Redemption” and, together with the Initial Redemption, the “Redemptions”). As used herein, the “Subsequent Redemption Time” shall mean the effective time of the Subsequent Redemption, and the “Redemption Time” shall mean (i) with respect to the Initial Redemption, the Initial Redemption Time and (ii) with respect to the Subsequent Redemption, the Subsequent Redemption Time.

​

5.3Each share of Series D Preferred Stock redeemed in any Redemption pursuant to this Section 5 shall be redeemed in consideration for the right to receive an amount equal to $0.01 in cash for each 10 whole shares of Series D Preferred Stock that are “beneficially owned” by the “beneficial owner” (as such terms are defined below) thereof as of immediately prior to the applicable Redemption Time and redeemed pursuant to such Redemption, payable upon receipt by the Corporation of a written request submitted by the applicable holder to the corporate secretary of the Corporation (each a “Redemption Payment Request”) following the applicable Redemption Time. Such Redemption Payment Request shall (i) be in a form reasonably acceptable to the Corporation (ii) set forth in reasonable detail the number of shares of Series D Preferred Stock beneficially owned by the holder at the applicable Redemption Time and include evidence reasonably satisfactory to the Corporation regarding the same, and (iii) set forth a calculation specifying the amount in cash owed to such Holder by the Corporation with respect to the shares of Series D Preferred Stock that were redeemed at the applicable Redemption Time. For the avoidance of doubt, the redemption consideration in respect of the shares of Series D Preferred Stock (or fractions thereof) redeemed in any Redemption pursuant to this Section 5: (x) shall entitle the former beneficial owners of less than ten whole shares of Series D Preferred Stock redeemed in any Redemption to no cash payment in respect thereof and (y) shall, in the case of a

3

former beneficial owner of a number of shares of Series D Preferred Stock (or fractions thereof) redeemed pursuant to any Redemption that is not equal to a whole number that is a multiple of ten, entitle such beneficial owner to the same cash payment, if any, in respect of such Redemption as would have been payable in such Redemption to such beneficial owner if the number of shares (or fractions thereof) beneficially owned by such beneficial owner and redeemed pursuant to such Redemption were rounded down to the nearest whole number that is a multiple of ten (such, that for example, the former beneficial owner of 25 shares of Series D Preferred Stock redeemed pursuant to any Redemption shall be entitled to receive the same cash payment in respect of such Redemption as would have been payable to the former beneficial owner of 20 shares of Series D Preferred Stock redeemed pursuant to such Redemption). As used herein, “Person” shall mean any individual, firm, corporation, partnership, limited liability company, trust or other entity, and shall include any successor (by merger or otherwise) to such entity. As used herein, a Person shall be deemed the “beneficial owner” of, and shall be deemed to “beneficially own,” any securities which such Person is deemed to beneficially own, directly or indirectly, within the meaning of Rule l3d-3 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended.

​

5.4From and after the time at which any shares of Series D Preferred Stock are called for redemption (whether automatically or otherwise) in accordance with Section 5.1 or Section 5.2, such shares of Series D Preferred Stock shall cease to be outstanding, and the only right of the former holders of such shares of Series D Preferred Stock, as such, will be to receive the applicable redemption price, if any. The shares of Series D Preferred Stock redeemed by the Corporation pursuant to this Certificate of Designation shall, upon such redemption, be automatically retired and restored to the status of authorized but unissued shares of Preferred Stock. Notwithstanding anything to the contrary herein or otherwise, and for the avoidance of doubt, any shares of Series D Preferred Stock (or fraction thereof) that have been redeemed pursuant to an Initial Redemption shall not be deemed to be outstanding for the purpose of voting or determining the number of votes entitled to vote on any matter submitted to stockholders (including the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split) from and after the time of the Initial Redemption. Notice of any meeting of stockholders for the submission to stockholders of any proposal to approve the Reverse Stock Split shall constitute notice of a redemption of shares of Series D Preferred Stock pursuant to an Initial Redemption and result in the automatic redemption of the applicable shares of Series D Preferred Stock (and/or fractions thereof) pursuant to the Initial Redemption at the Initial Redemption Time pursuant to Section 5.1 hereof. Notice by the Corporation of the approval by the Corporation’s stockholders of the Reverse Stock Split, whether by press release or a filing with the Securities and Exchange Commission, shall constitute a notice of redemption of shares of Series D Preferred Stock pursuant to a Subsequent Redemption and result in the automatic redemption of the applicable shares of Series D Preferred Stock (and/or fractions thereof) pursuant to the Subsequent Redemption at the Subsequent Redemption Time pursuant to Section 5.2 hereof. In connection with the filing of this Certificate of Designation, the Corporation has set apart funds for payment for the redemption of all shares of Series D Preferred Stock pursuant to the Redemptions and shall continue to keep such funds apart for such payment through the payment of the purchase price for the redemption of all such shares.

​

4

6.Transfer. Shares of Series D Preferred Stock will be uncertificated and represented in book-entry form. No shares of Series D Preferred Stock may be transferred by the holder thereof except in connection with a transfer by such holder of any shares of Common Stock held thereby, in which case a number of one one-thousandths (1/1,000ths) of a share of Series D Preferred Stock equal to the number of shares of Common Stock to be transferred by such holder shall be automatically transferred to the transferee of such shares of Common Stock. Notice of the foregoing restrictions on transfer shall be given in accordance with Section 151 of the DGCL.

​

7.Fractional Shares. The Series D Preferred Stock may be issued in whole shares or in any fraction of a share that is one one-thousandth (1/1,000th) of a share or any integral multiple of such fraction, which fractions shall entitle the holder, in proportion to such holder’s fractional shares, to exercise voting rights, participate in distributions upon a Dissolution and have the benefit of any other rights of holders of Series D Preferred Stock.

​

8.Severability. Whenever possible, each provision hereof shall be interpreted in a manner as to be effective and valid under applicable law, but if any provision hereof is held to be prohibited by or invalid under applicable law, then such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating or otherwise adversely affecting the remaining provisions hereof.

​

[Remainder of page intentionally left blank.]

​

5

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Designation of Series D Preferred Stock to be duly executed by the undersigned duly authorized officer as of this 24th day of May, 2023.

Ampio Pharmaceuticals, Inc.

By: /s/ Michael A. Martino​ ​​ ​​ ​
Name: Michael A. Martino
Title: Chief Executive Officer

6

 EX-99.1 4 ampe-20230524xex99d1.htm EX-99.1

Exhibit 99.1

Graphic

Ampio Pharmaceuticals Announces Series D Preferred Stock Dividend to its Holders of Common Stock

​

ENGLEWOOD, Colo., May 26, 2023 – Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company”) today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on June 8, 2023. The shares of Series D Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on June 8, 2023. Shares of Series D Preferred Stock will be uncertificated and represented in book-entry form.

The outstanding shares of Series D Preferred Stock will vote together with the outstanding shares of the Company's common stock, as a single class, exclusively with respect to a reverse stock split, as well as any proposal to adjourn any meeting of stockholders called for the purpose of voting on the reverse stock split, and will not be entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law. Subject to certain limitations, each outstanding share of Series D Preferred Stock will have 1,000,000 votes per share (or 1,000 votes per one one-thousandth of a share of Series D Preferred Stock). The vote of each share of Series D Preferred Stock (or fraction thereof) entitled to vote on the specified matters will be cast in the same manner as the vote cast, if any, of the share of Common Stock (or fraction thereof) in respect of which such share of Series D Preferred Stock (or fraction thereof) was issued.

All shares of Series D Preferred Stock that are not present in person or by proxy at the meeting of stockholders held to vote on the reverse stock split as of immediately prior to the opening of the polls at such meeting will automatically be redeemed by the Company. Any shares of Series D Preferred Stock (or fraction thereof) that have been so redeemed will not be deemed to be outstanding for the purpose of voting or determining the number of votes entitled to vote on any matter submitted to stockholders. Additionally, any outstanding shares of Series D Preferred Stock that have not been so redeemed will be redeemed if such redemption is ordered by the Company's Board of Directors or automatically upon the approval by the Company's stockholders of an amendment to the Company's certificate of incorporation effecting the reverse stock split at such meeting. After the redemption of the Series D Preferred Stock in full, the Company's capitalization structure will be as it was prior to the dividend of the Series D Preferred Stock, with the same number of common shares outstanding as were outstanding prior to the June 8, 2023 dividend of the Series D Preferred Stock, without giving effect to the reverse stock split, the issuance of common stock in connection with a stock option exercise or other sales of common stock by the Company.

The redeemed shares of Series D Preferred Stock will automatically retired and restored to the status of authorized but unissued shares of Preferred Stock.

Shares of Series D Preferred Stock will not be transferable by any holder thereof except in connection with a transfer by such holder of any shares of the Company's common stock held by such holder. In that case, a number of one one-thousandth of a share of Series D Preferred Stock equal to the number of shares of the

Company's common stock to be transferred by such holder would be transferred to the transferee of such shares of common stock.

Further details regarding the Series D Preferred Stock will be contained in a report on Form 8-K to be filed by the Company with the Securities and Exchange Commission.

Caution Regarding Forward-Looking Statements

All statements other than statements of historical facts contained in this letter, including statements regarding our anticipated future clinical developments, future financial position, and plans and objectives of management for future operations, are forward-looking statements. Words such as “may”, “will”, “should”, “forecast”, “could”, “expect”, “suggest”, “believe”, “estimate”, “continue”, “anticipate”, “intend”, “ongoing”, “opportunity”, “potential”, “predicts”, “seek”, “plan,” or similar words, or the negatives of such terms or other variations on such terms or comparable terminology, typically identify forward-looking statements.

Forward-looking statements are based on certain assumptions and expectations of future events and trends that are subject to risks and uncertainties including: we are dependent on the success of our OA-20X program and we cannot be certain that any preclinical data will support its further development; there can be no assurance that we will be successful in identifying or completing any strategic alternative or that any such strategic alternative will yield value for our stockholders; we may not be able to manage third parties to provide timely, high quality, and cost-effective services to us; our history of losses and our cash resources available to execute our business plan over the next twelve months raise substantial doubt about our ability to continue as a going concern; we are involved in legal proceedings that likely will adversely affect our financial position and our pursuit of strategic alternatives; we may need additional capital to fund our future operations, the development of the OA-20X program and any strategic transaction; we are dependent on adequate protection of our patent and proprietary rights; the price of our stock has been and may continue to be extremely volatile; if we cannot continue to satisfy the NYSE American continued listing requirements and rules, our securities may be delisted, which could negatively impact the price of our securities; and other risks described in “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and subsequent periodic reports filed with the SEC.

We undertake no obligation to update or revise publicly any forward-looking statements to reflect events or circumstances after the date of such statements for any reason, except as otherwise required by law.

​

For more information, contact:

​

Ampio Pharmaceuticals, Inc.

Michael Martino

Chief Executive Officer

mmartino@ampiopharma.com

 GRAPHIC 5 ampe-20230524x8k006.jpg GRAPHIC begin 644 ampe-20230524x8k006.jpg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end GRAPHIC 6 ampe-20230524xex99d1001.jpg GRAPHIC begin 644 ampe-20230524xex99d1001.jpg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end EX-101.SCH 7 ampe-20230524.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 8 ampe-20230524_lab.xml EX-101.LAB EX-101.PRE 9 ampe-20230524_pre.xml EX-101.PRE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 24, 2023
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date May 24, 2023
Entity File Number 001-35182
Entity Registrant Name AMPIO PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 26-0179592
Entity Address, Address Line One 373 Inverness Parkway, Suite 200
Entity Address, City or Town Englewood
Entity Address, State or Province CO
Entity Address, Postal Zip Code 80112
City Area Code 720
Local Phone Number 437-6500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol AMPE
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
Entity Central Index Key 0001411906
Amendment Flag false
Current Fiscal Year End Date --12-31
XML 11 ampe-20230524x8k_htm.xml IDEA: XBRL DOCUMENT 0001411906 2023-05-24 2023-05-24 0001411906 false --12-31 8-K 2023-05-24 AMPIO PHARMACEUTICALS, INC. DE 001-35182 26-0179592 373 Inverness Parkway, Suite 200 Englewood CO 80112 720 437-6500 false false false false Common Stock, $0.0001 par value AMPE NYSEAMER false EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

$ MNE8<.&7J/P$ #P" / " 7X0 !X;"]W;W)K8F]O:RYX M;6Q02P$"% ,4 " "'A+I6)!Z;HJT #X 0 &@ @ 'J M$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "'A+I6 M99!YDAD! #/ P $P @ '/$@ 6T-O;G1E;G1?5'EP97-= :+GAM;%!+!08 "0 ) #X" 9% ! end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ampe-20230524x8k.htm ampe-20230524.xsd ampe-20230524_lab.xml ampe-20230524_pre.xml ampe-20230524xex3d1.htm ampe-20230524xex3d2.htm ampe-20230524xex99d1.htm ampe-20230524x8k006.jpg http://xbrl.sec.gov/dei/2022 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ampe-20230524x8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "ampe-20230524x8k.htm" ] }, "labelLink": { "local": [ "ampe-20230524_lab.xml" ] }, "presentationLink": { "local": [ "ampe-20230524_pre.xml" ] }, "schema": { "local": [ "ampe-20230524.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ampe", "nsuri": "http://www.ampiopharma.com/20230524", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "ampe-20230524x8k.htm", "contextRef": "Duration_5_24_2023_To_5_24_2023_il-vd937TE2yM2lz_-zuMg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "ampe-20230524x8k.htm", "contextRef": "Duration_5_24_2023_To_5_24_2023_il-vd937TE2yM2lz_-zuMg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "ampe_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.ampiopharma.com/20230524", "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 18 0001558370-23-010552-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-010552-xbrl.zip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ﾁ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end